A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral UE2343 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2017
At a glance
- Drugs UE 2343 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 26 Apr 2017 Results from this trial have been published in the British Journal of Pharmacology in February 2017, according to an Actinogen Medical media release.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jan 2013 New trial record